| Not Yet Recruiting | SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer NCT07322341 | University of Washington | Phase 2 |
| Recruiting | GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cel NCT07017829 | Roswell Park Cancer Institute | Phase 2 |
| Not Yet Recruiting | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tum NCT07405086 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunother NCT06731270 | Emory University | Phase 2 |
| Recruiting | Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung C NCT06096844 | National Cancer Institute (NCI) | Phase 3 |
| Recruiting | Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Met NCT06249282 | City of Hope Medical Center | Phase 1 |
| Recruiting | LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia NCT06073431 | University of Rochester | — |
| Recruiting | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor C NCT05967533 | University of California, Davis | Phase 1 |
| Unknown | EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer NCT05498389 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Tai-Chi and Aerobic Exercise to Improve Emotional Symptom Cluster in Late-stage Lung Cancer Patients NCT05778708 | The University of Hong Kong | N/A |
| Terminated | Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer Related Fatigue NCT05407038 | Mayo Clinic | N/A |
| Active Not Recruiting | Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small C NCT05334329 | University of California, Irvine | Phase 1 |
| Completed | Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial NCT05339022 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual NCT05096663 | SWOG Cancer Research Network | Phase 2 / Phase 3 |
| Active Not Recruiting | Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer NCT05166616 | City of Hope Medical Center | Phase 1 |
| Recruiting | ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSC NCT05198154 | Fang Wu | — |
| Terminated | A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell NCT04856176 | Tufts Medical Center | Phase 2 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or C NCT04491942 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progress NCT04902040 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC NCT04754815 | Shirish Gadgeel | Phase 2 |
| Recruiting | MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer NCT04762199 | Emory University | Phase 1 |
| Terminated | Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer NCT04396535 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lun NCT03831932 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing P NCT04186988 | University of California, Davis | EARLY_Phase 1 |
| Recruiting | Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change NCT03191149 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung C NCT02983578 | M.D. Anderson Cancer Center | Phase 2 |